Q1 EPS Estimate for X4 Pharmaceuticals Lifted by Analyst

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) – Analysts at HC Wainwright boosted their Q1 2025 earnings per share estimates for shares of X4 Pharmaceuticals in a research report issued to clients and investors on Thursday, March 27th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings per share of ($0.02) for the quarter, up from their previous estimate of ($0.15). HC Wainwright has a “Buy” rating and a $1.50 price target on the stock. The consensus estimate for X4 Pharmaceuticals’ current full-year earnings is ($0.68) per share. HC Wainwright also issued estimates for X4 Pharmaceuticals’ Q2 2025 earnings at ($0.13) EPS, Q3 2025 earnings at ($0.09) EPS, Q4 2025 earnings at ($0.08) EPS, FY2025 earnings at ($0.32) EPS, FY2026 earnings at ($0.23) EPS and FY2027 earnings at ($0.16) EPS.

Separately, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $3.00 price objective on shares of X4 Pharmaceuticals in a research report on Wednesday, March 26th.

X4 Pharmaceuticals Price Performance

XFOR stock opened at $0.24 on Monday. The stock has a 50-day moving average price of $0.43 and a two-hundred day moving average price of $0.52. X4 Pharmaceuticals has a 1 year low of $0.23 and a 1 year high of $1.60. The stock has a market cap of $41.05 million, a PE ratio of -2.63 and a beta of 0.39. The company has a current ratio of 4.89, a quick ratio of 4.80 and a debt-to-equity ratio of 1.26.

X4 Pharmaceuticals (NASDAQ:XFOR) last issued its quarterly earnings data on Tuesday, March 25th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.03). The firm had revenue of $1.43 million for the quarter, compared to the consensus estimate of $1.07 million.

Hedge Funds Weigh In On X4 Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the company. Acorn Capital Advisors LLC acquired a new stake in X4 Pharmaceuticals in the fourth quarter valued at $5,363,000. Geode Capital Management LLC grew its holdings in X4 Pharmaceuticals by 1.4% during the fourth quarter. Geode Capital Management LLC now owns 3,497,212 shares of the company’s stock worth $2,566,000 after purchasing an additional 49,700 shares during the period. State Street Corp increased its position in X4 Pharmaceuticals by 6.8% during the third quarter. State Street Corp now owns 2,952,895 shares of the company’s stock worth $1,976,000 after buying an additional 189,105 shares during the last quarter. Northern Trust Corp raised its stake in X4 Pharmaceuticals by 2.9% in the fourth quarter. Northern Trust Corp now owns 1,357,539 shares of the company’s stock valued at $996,000 after buying an additional 37,940 shares during the period. Finally, Point72 Asset Management L.P. raised its stake in X4 Pharmaceuticals by 4.0% in the fourth quarter. Point72 Asset Management L.P. now owns 650,000 shares of the company’s stock valued at $477,000 after buying an additional 24,948 shares during the period. 72.03% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at X4 Pharmaceuticals

In other news, CEO Paula Ragan sold 76,473 shares of the company’s stock in a transaction that occurred on Friday, January 24th. The stock was sold at an average price of $0.45, for a total transaction of $34,412.85. Following the sale, the chief executive officer now owns 1,087,386 shares in the company, valued at $489,323.70. This represents a 6.57 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Adam S. Mostafa sold 74,773 shares of the stock in a transaction that occurred on Friday, January 24th. The shares were sold at an average price of $0.45, for a total value of $33,647.85. The disclosure for this sale can be found here. Insiders have sold a total of 202,663 shares of company stock valued at $91,198 over the last 90 days. 1.62% of the stock is owned by corporate insiders.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.